Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies
Vitaly Chasov, Ekaterina Zmievskaya, Irina Ganeeva, et al.
Antibodies (2024) Vol. 13, Iss. 1, pp. 10-10
Open Access | Times Cited: 18

Showing 18 citing articles:

Advances in Synthetic Immunology for Targeted Treatment of Systemic Autoimmune Diseases: Opportunities, Challenges, and Future Directions
Galih Januar Adytia, Henry Sutanto, Laras Pratiwi, et al.
Immuno (2025) Vol. 5, Iss. 1, pp. 6-6
Open Access | Times Cited: 1
Engineering strategies to safely drive CAR T-cells into the future
Matteo Rossi, Eytan Breman
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 9
Frontiers in CAR-T cell therapy for autoimmune diseases
Yan-Ruide Li, Zibai Lyu, Yuning Chen, et al.
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 9, pp. 839-857
Open Access | Times Cited: 9
Cell therapy for scleroderma: progress in mesenchymal stem cells and CAR-T treatment
Liting Chen, Ri-Zhen Huang, Caizhi Huang, et al.
Frontiers in Medicine (2025) Vol. 11
Open Access
T-regulatory cells for the treatment of autoimmune diseases
Marina Fisher, С. В. Сенников
Frontiers in Immunology (2025) Vol. 16
Open Access
Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders
Azhagu Madhavan Sivalingam
Clinical Reviews in Allergy & Immunology (2025) Vol. 68, Iss. 1
Closed Access
Vaccine adjuvants for immunotherapy: type, mechanisms and clinical applications
Nimeet Desai, Sherrin Gotru, Sagar Salave, et al.
Frontiers in Biomaterials Science (2025) Vol. 4
Open Access
A new therapeutic pathway in autoimmune diseases: chimeric antigen receptor T cells (CAR-T) targeting specific cell subtypes or antigen-specific B lymphocytes—a brief review
María Fernanda Segovia, Diana Landoni, Yohana Defranchi, et al.
Exploration of Immunology (2025) Vol. 5
Open Access
Pharmacotherapy of autoimmune rheumatic diseases – from monoclonal antibodies to CAR T cells: 20 years later
Е. Л. Насонов, A. G. Rumyantsev, Samsonov MIu
Rheumatology Science and Practice (2024) Vol. 62, Iss. 3, pp. 262-279
Open Access | Times Cited: 2
Incidentally cured psoriasis in a patient with refractory/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report
Song-yun Wang, Weiming An, Zuming Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Systemic Autoimmune Diseases
Ananya Reddy Cingireddy, Brianna Flores, John Wuthrich, et al.
Cureus (2024)
Open Access | Times Cited: 1
Immunogenomic Exploration of Cutaneous Manifestations and Therapeutic Targets in Systemic Sclerosis
Vivian Li DO
Clinical Dermatology Open Access Journal (2024) Vol. 9, Iss. 2
Open Access | Times Cited: 1
Making the effect visible – OX40 targeting nanobodies for in vivo imaging of activated T cells
Desiree I. Frecot, Simone Blaess, Teresa R. Wagner, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Revolutionizing Cancer Treatment: Unleashing the Power of Combining Oncolytic Viruses with CAR-T Cells
Zhang Lin, Shuxian Guo, ShuYing Chang, et al.
Anti-Cancer Agents in Medicinal Chemistry (2024) Vol. 24, Iss. 19, pp. 1407-1418
Closed Access
CAR-T Therapy can be a Useful Treatment Modality for more than Just Hematologic Malignancies
Kazuhiro Ikegame
Internal Medicine (2024)
Open Access
Strategies and delivery systems for cell-based therapy in autoimmunity
Matteo Puccetti, Claudio Costantini, Aurélie Schoubben, et al.
Frontiers in Drug Delivery (2024) Vol. 4
Open Access
Making the effect visible – OX40 targeting nanobodies forin vivoimaging of activated T cells
Desiree I. Frecot, Simone Blaess, Teresa R. Wagner, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
The next frontier in multiple sclerosis therapies: Current advances and evolving targets.
K. Trideva Sastri, Neha Gupta, Anbarasu Kannan, et al.
European Journal of Pharmacology (2024) Vol. 985, pp. 177080-177080
Closed Access
Page 1

Scroll to top